About Antiva Biosciences
Antiva Biosciences, Inc. is a clinical stage venture-backed biopharmaceutical company developing a novel, first in class, topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions (CIN 2,3). Although HPV is the most common sexually transmitted infection in the world, there are currently no approved therapeutic options. Moreover, the overall burden of cervical cancer associated with HPV and related deaths rank fourth among all cancers for women.
Our lead product, ABI-2280, for the treatment of high-risk HPV and CIN 2,3, utilizes antiviral prodrug chemistry developed by Dr. Karl Hostetler at the University of California San Diego. Our goal is to provide a treatment for high-risk HPV infection, where none currently exists, and a non-surgical alternative for CIN 2,3 that preserves women’s reproductive health.
“I treated women for cervical and vulvar precancer for nearly 40 years and always hoped that a topical treatment would someday be available that would alleviate the problems associated with surgical approaches to treatment and provide greater accessibility to treatment for underserved women especially limited by lack of medical professionals trained in these procedures, whether in rural or other underserved areas in the US or internationally. I wish Antiva Biosciences well in their endeavor to provide this new treatment option.”
